Posts tagged “Genomics”
Federal health officials are easing access to DNA tests used to screen parents for devastating genetic disorders that can be passed on to their children. The surprise announcement Thursday offers a path forward for Google-backed genetic testing firm 23andMe, which previously clashed with regulators over its direct-to-consumer technology.
Feeding a world population the United Nations estimates will hit 9 billion by 2050 is only one of the social problems caused by an increasing number of people, the director of of the US Department of Agriculture's National Institute of Food and Agriculture tells the AgBio Summit in Raleigh. WRAL TechWire's Allan Maurer reports the details for our Insiders.
Agrochemicals giant Syngenta is facing a growing number of lawsuits challenging its release of a genetically modified corn seed that China had not approved for import, with losses to farmers estimated to be at least $1 billion.
As NC State prepares to host the AGBIO Summit, the dean of the university's College of Agriculture and Life Sciences says the event will help showcase North Carolina as the "Mecca, the hub for agio." The theme of the event: Feeding a world of 9 billion people in 2050. And action is required, reports WRAL TechWire's Allan Maurer.
It's an eye-catching angle in the story of an experimental treatment for Ebola: The drug comes from tobacco plants that were turned into living pharmaceutical factories. And one of the emerging players is Medicago, which operates a production facility in RTP.
Pfizer is teaming up with DNA testing company 23andMe to study the possible genetic underpinnings of inflammatory bowel disease, a hard-to-treat ailment that affects an estimated 1.4 million Americans.
The future of food research is taking root in some very fertile ground - the minds of students working on the N.C. Research Campus. In an Insider exclusive for WRAL TechWire, read how a new internship program encourages STEM careers
Morrisville-based Gentris, which provides storage and testing services to research laboratories, has received a $4.75 million buy-out offer from New Jersey-based Cancer Genetics,
Triangle-based Metabolon, which recently struck a deal with DNA pioneer Craig Venter to help us find ways to live longer, has another high-profile partner: GlaxoSmithKline. The two neighbors disclosed a new collaboration agreement Tuesday.
Baxter International is acquiring Chapel Hill-based Chatham Therapeutics to gain control of gene-based therapy technology focused on hemophilia. The deal includes a $70 million upfront payment. Additional payments could be made based on development, regulatory and commercial milestones.
I meet entrepreneurs all over the world who think that venture capital is a prerequisite for starting a company. They write business plans and ask for introductions to venture capitalists. I tell them that they should instead bootstrap their startups; that what would have cost millions of dollars a few years ago now costs thousands. This story is about one startup that bootstrapped, rebooted and sold for millions.
Opinion: Hardly a week goes by without the announcement of a major scientific breakthrough in genomics. This means that medicine will, within a few years, start advancing at the same pace as the Internet and software. And, we will see a revolution in health care.
J. Craig Venter, the man who raced the U.S. government to sequence the first human genome, has a new goal: Help everyone live to 100, in good health. And one of his first partners is RTP-based Metabolon, where he serves as a scientific adviser.
Metabolon will utilize its proprietary molecular technology to help Human Longevity Inc., the new company led by genome pioneer Craig Venter, to find indications of disease and gene mutations.
A grant from the National Human Genome Research Institute will enable RTI International to enhance genomic research through its no-cost PhenX Toolkit.
The N.C. Biotech Center notes recent wins of three Triangle life science firms whose start included support from the Biotech Center
Analysis: At the CED Life Science Conference 2013, we will address the changes, challenges and opportunities in the medical device industry and study working models of successful medtech businesses.